BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21784955)

  • 1. Circulating soluble CD30 and future risk of lymphoma; evidence from two prospective studies in the general population.
    Vermeulen R; Hosnijeh FS; Portengen L; Krogh V; Palli D; Panico S; Tumino R; Sacredote C; Purdue M; Lan Q; Rothman N; Vineis P
    Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1925-7. PubMed ID: 21784955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses.
    Hosnijeh FS; Portengen L; Späth F; Bergdahl IA; Melin B; Mattiello A; Masala G; Sacerdote C; Naccarati A; Krogh V; Tumino R; Chadeau-Hyam M; Vineis P; Vermeulen R
    Int J Cancer; 2016 May; 138(10):2357-67. PubMed ID: 26684261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD30 ligand in lymphoma patients with CD30+ tumors.
    Younes A; Consoli U; Snell V; Clodi K; Kliche KO; Palmer JL; Gruss HJ; Armitage R; Thomas EK; Cabanillas F; Andreeff M
    J Clin Oncol; 1997 Nov; 15(11):3355-62. PubMed ID: 9363866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-dependent changes of serum soluble CD30 concentration in children.
    Chrul S; Polakowska E
    Pediatr Transplant; 2011 Aug; 15(5):515-8. PubMed ID: 21672104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posttransplant soluble CD30 as a predictor of acute renal allograft rejection.
    Kamali K; Abbasi MA; Farokhi B; Abbasi A; Fallah P; Seifee MH; Ghadimi N; Rezaie AR
    Exp Clin Transplant; 2009 Dec; 7(4):237-40. PubMed ID: 20353374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble CD30 serum levels in atopic dermatitis and bronchial asthma and its relationship with disease severity in pediatric age.
    Heshmat NM; El-Hadidi ES
    Pediatr Allergy Immunol; 2006 Jun; 17(4):297-303. PubMed ID: 16771784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma.
    Breen EC; Fatahi S; Epeldegui M; Boscardin WJ; Detels R; Martínez-Maza O
    Tumour Biol; 2006; 27(4):187-94. PubMed ID: 16651853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between serum soluble CD30 and serum creatinine before and after renal transplantation.
    López-Hoyos M; San Segundo D; Benito MJ; Fernández-Fresnedo G; Ruiz JC; Rodrigo E; Gómez-Alamillo C; Benito A; Arias M
    Transplant Proc; 2008 Nov; 40(9):2903-5. PubMed ID: 19010142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-transplant soluble CD30 is associated with bronchiolitis obliterans syndrome after lung transplantation.
    Bauwens AM; van de Graaf EA; van Ginkel WG; van Kessel DA; Otten HG
    J Heart Lung Transplant; 2006 Apr; 25(4):416-9. PubMed ID: 16563971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC.
    Plattel WJ; Alsada ZN; van Imhoff GW; Diepstra A; van den Berg A; Visser L
    Br J Haematol; 2016 Dec; 175(5):868-875. PubMed ID: 27610595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy.
    Grenzi PC; Campos ÉF; Tedesco-Silva H; Felipe CR; Franco MF; Soares MF; Medina-Pestana JO; Gerbase-Delima M
    Transpl Immunol; 2013 Dec; 29(1-4):34-8. PubMed ID: 23928467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?
    Altermann W; Schlaf G; Rothhoff A; Seliger B
    Nephrol Dial Transplant; 2007 Oct; 22(10):2795-9. PubMed ID: 17616534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma.
    Purdue MP; Lan Q; Martinez-Maza O; Oken MM; Hocking W; Huang WY; Baris D; Conde B; Rothman N
    Blood; 2009 Sep; 114(13):2730-2. PubMed ID: 19638620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fluticasone propionate on soluble CD30 release in patients with severe allergic asthma.
    Purello-D'Ambrosio F; Gangemi S; Ruello G; Marotta G; Merendino RA
    J Investig Allergol Clin Immunol; 2000; 10(5):283-5. PubMed ID: 11108439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes.
    Purdue MP; Lan Q; Langseth H; Grimsrud TK; Hildesheim A; Rothman N
    Int J Cancer; 2020 Jun; 146(12):3312-3319. PubMed ID: 31523805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation between pretransplant serum levels of soluble CD30 and acute rejection during the first 6 months after a kidney transplant.
    Shooshtarizadeh T; Mohammadali A; Ossareh S; Ataipour Y
    Exp Clin Transplant; 2013 Jun; 11(3):229-33. PubMed ID: 23477385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating sCD27 and sCD30 in pre-diagnostic samples collected fifteen years apart and future non-Hodgkin lymphoma risk.
    Purdue MP; Lan Q; Hoffman-Bolton J; Hildesheim A; Callahan CL; Strickland P; Visvanathan K; Rothman N
    Int J Cancer; 2019 Apr; 144(8):1780-1785. PubMed ID: 30230539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease.
    Ihn H; Yazawa N; Kubo M; Yamane K; Sato S; Fujimoto M; Kikuchi K; Soma Y; Tamaki K
    J Rheumatol; 2000 Mar; 27(3):698-702. PubMed ID: 10743811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
    Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
    Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30.
    Gerli R; Lunardi C; Bocci EB; Bobbio-Pallavicini F; Schillaci G; Caporali R; Bistoni O; Pirro M; Pitzalis C; Montecucco C
    J Rheumatol; 2008 Jan; 35(1):14-9. PubMed ID: 18061981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.